ArticleTranslational cancer research2026
CSN3 promotes gastric cancer progression and is associated with immune infiltration and inflammatory signaling.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CSN3 promotes colorectal cancer cell progression through activation of the PI3K/AKT/mTOR pathway.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Casein kappa (CSN3) is a milk protein-encoding gene, and its expression pattern and biological significance in gastric cancer (GC) remain unclear, this study aims to explore expression and function of CSN3 in GC. Methods: CSN3 expression was assessed in GC tissues and cell lines. Its biological effects were examined Results: CSN3 expression was elevated in GC and was positively associated with deeper tumor invasion, lymph node metastasis, advanced Tumor-Node-Metastasis (TNM) stage, and poorer prognosis. Knockdown of CSN3 inhibited GC cell proliferation and migration while promoting apoptosis. CSN3 overexpression promoted tumor growth Conclusions: CSN3 is upregulated in GC and is associated with malignant progression and poor prognosis. CSN3 may promote GC progression partly through modulation of NOD1/RIP2/NF-κB-related inflammatory signaling and remodeling of the tumor immune microenvironment. These findings suggest that CSN3 may serve as a potential biomarker in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.